Citigroup’s Neon Therapeutics, Inc. Common Stock NTGN Stock Holding History

Citigroup’s Portfolio NTGN Stock Details NTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-4,010	Closed	-$11K	–	7846
2020 Q1	$11K	Buy	4,010 +1,175	+41%	+$1.93K	﹤0.01%	7026
2019 Q4	$3K	Buy	2,835 +1,770	+166%	+$2.83K	﹤0.01%	7521
2019 Q3	$2K	Sell	1,065 -2,547	-71%	-$7.75K	﹤0.01%	7584
2019 Q2	$17K	Sell	3,612 -674	-16%	-$3.77K	﹤0.01%	7152
2019 Q1	$28K	Buy	4,286 +2,624	+158%	+$13.7K	﹤0.01%	6781
2018 Q4	$9K	Sell	1,662 -102	-6%	-$714	﹤0.01%	7218
2018 Q3	$15K	Buy	+1,764	New	+$19.6K	﹤0.01%	7222

Citigroup's NTGN Position: Q2 2020 in Review

Citigroup sold out of Neon Therapeutics, Inc. Common Stock (NTGN) in Q2 2020, closing a stake of 4,010 shares — an estimated $11K sold.

Citigroup first reported a position in NTGN in Q3 2018 and held it in 7 quarters. The position peaked at $28K in Q1 2019. 0 funds tracked by Wall St. Rank hold NTGN as of Q2 2020.

Citigroup reported no remaining Neon Therapeutics, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
Citigroup sold 4,010 Neon Therapeutics, Inc. Common Stock shares in Q2 2020, an estimated $11K.
Citigroup first reported a position in Neon Therapeutics, Inc. Common Stock in Q3 2018 and held it in 7 quarters.
Citigroup's Neon Therapeutics, Inc. Common Stock position peaked at $28K in Q1 2019.
0 funds tracked by Wall St. Rank held Neon Therapeutics, Inc. Common Stock as of Q2 2020.

Based on Citigroup's 13F filing for Q2 2020, filed 12 Aug 2020.